Turn Therapeutics Secures $25M for Skin Pipeline
LOS ANGELES, USA | March 24, 2026 Turn Therapeutics, Inc., a clinical-stage dermatology-focused biotechnology company, has announced a strategic...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
LOS ANGELES, USA | March 24, 2026 Turn Therapeutics, Inc., a clinical-stage dermatology-focused biotechnology company, has announced a strategic...
SAN FRANCISCO & BOSTON, USA | March 24, 2026 Apogee Therapeutics, Inc. has successfully announced the pricing of its...
San Francisco, California, USA | March 20, 2026 Nektar Therapeutics has announced that Phase 2b clinical data for rezpegaldesleukin,...
FRIENDSWOOD, Texas, Feb. 19, 2026 — Castle Biosciences announced prospective clinical validation data published in the Journal of the...
PALO ALTO, Calif. & NEW YORK, Feb. 10, 2026 — Clinical-stage biotechnology company Evommune announced positive top-line results from...
SOUTH SAN FRANCISCO, CALIFORNIA | January 27, 2026 — TRexBio, Inc., a clinical-stage biotechnology company focused on precision immunoregulatory...
